Published in
Springer, Diabetologia, 7(62), p. 1154-1166, 2019
DOI: 10.1007/s00125-019-4859-4
Links
Tools
Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease
Journal article published in 2019 by
Hiddo J. L. Heerspink,
Paul Perco 
,
Skander Mulder,
Johannes Leierer ,
Michael K. Hansen,
Andreas Heinzel,
Gert Mayer
,
Skander Mulder,
Johannes Leierer ,
Michael K. Hansen,
Andreas Heinzel,
Gert Mayer
This paper is made freely available by the publisher.
Full text: Download
Published version:
archiving forbidden
Data provided by 